Aspire Biopharma Holdings, Inc. (ASBPW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 35K 70K 105K Q2 '26: 97.7K Q2 '26

Gross Profit TTM

0 7K 14K 21K Q2 '26: 17.9K Q2 '26

Operating Income TTM

-21M -14M -7M 0 7M 14M 21M Q2 '25: -17.2M Q3 '25: -18.2M Q4 '25: -19.4M Q1 '26: -5.4M Q2 '26: -7.3M Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-27M -18M -9M 0 9M 18M 27M Q1 '22: -106.3K Q2 '22: 16.8K Q3 '22: 1.1M Q4 '22: 3.3M Q1 '23: 6.3M Q2 '23: 8M Q3 '23: 6.8M Q4 '23: 4.5M Q1 '24: 1.4M Q2 '24: -548.1K Q3 '24: -695.1K Q4 '24: -1.3M Q1 '25: -17M Q2 '25: -18.9M Q3 '25: -20.5M Q4 '25: -24.5M Q1 '26: -11.8M Q2 '26: -11M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 30K 60K 90K Q2 '26: 79.7K Q2 '26

Operating Cash Flow TTM

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q1 '22: -1.4M Q2 '22: -1.5M Q3 '22: -1.4M Q4 '22: -1.4M Q1 '23: -303K Q2 '23: -454.6K Q3 '23: -532.8K Q4 '23: -653.1K Q1 '24: -664K Q2 '24: -530.3K Q3 '24: -900.9K Q4 '24: -265.2K Q1 '25: -1.8M Q2 '25: -2.9M Q3 '25: -3.5M Q4 '25: -4.9M Q1 '26: -6.2M Q2 '26: -7.2M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 20M 40M 60M Q3 '24: 27.6M Q1 '25: 31.6K Q2 '25: 41.1K Q3 '25: 49.5M Q1 '26: 156.7K Q2 '26: 1M Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-600.00 -400.00 -200.00 0.00 200.00 400.00 600.00 Q2 '25: -554.96 Q3 '25: -554.99 Q2 '25 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.